Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives, Ann Oncol Off J Eur Soc Med Oncol, vol.18, pp.1927-1934, 2006. ,
Neoadjuvant chemotherapy for operable breast cancer, Br J Surg, vol.94, pp.1189-1200, 2007. ,
Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis, J Natl Cancer Inst, vol.97, pp.188-194, 2005. ,
Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus-Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts, Breast Care Basel Switz, vol.10, pp.211-219, 2015. ,
, Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials, Lancet Oncol, vol.19, issue.17, pp.30777-30782, 2018.
Biomarkers of residual disease after neoadjuvant therapy for breast cancer, Nat Rev Clin Oncol, vol.13, pp.487-503, 2016. ,
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis, Lancet Lond Engl, vol.384, pp.164-172, 2014. ,
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes, J Clin Oncol Off J Am Soc Clin Oncol, vol.30, pp.1796-1804, 2012. ,
Adding Adjuvant Systemic Treatment after Neoadjuvant Therapy in Breast Cancer: Review of the Data, Curr Oncol Rep, vol.19, p.28733827, 2017. ,
The use of alternate, noncross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial, J Clin Oncol Off J Am Soc Clin Oncol, vol.22, pp.2294-2302, 2004. ,
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27, J Clin Oncol Off J Am Soc Clin Oncol, vol.24, pp.2019-2027, 2006. ,
Adjuvant extension of chemotherapy after neoadjuvant therapy may not improve outcome in early-stage breast cancer, Eur J Surg Oncol EJSO, vol.35, pp.798-804, 2009. ,
Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer, Clin Breast Cancer, vol.15, pp.325-331, 2015. ,
Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer-The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29), Eur J Cancer, vol.64, pp.12-21, 2016. ,
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy, New England Journal of Medicine, pp.2147-2159, 2017. ,
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology, pp.403-410, 1991. ,
Recommandations pour l'é valuation immunohistochimique des ré cepteurs hormonaux sur coupes en paraffine dans les carcinomes mammaires Mise à jour 1999. /data/revues/02426498/00190004/336, p.11, 2008. ,
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer, Journal of Clinical Oncology, vol.1, pp.3997-4013, 2013. ,
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol, vol.26, issue.5, pp.8-30, 2015. ,
Preoperative radio-chemotherapy in early breast cancer patients: long-term results of a phase II trial, Radiother Oncol J Eur Soc Ther Radiol Oncol, vol.102, pp.82-88, 2012. ,
Prospective and comparative evaluation of the toxicity of adjuvant concurrent chemoradiotherapy after neoadjuvant chemotherapy for breast cancer, Am J Clin Oncol, vol.36, pp.425-429, 2013. ,
Invited commentary: propensity scores, Am J Epidemiol, vol.150, pp.327-333, 1999. ,
, Rev Med Interne, vol.29, pp.255-258, 2008.
Variable selection for propensity score models, Am J Epidemiol, vol.163, pp.1149-1156, 2006. ,
Propensity score adjustment for pretreatment differences between hospitalized and ambulatory patients with community-acquired pneumonia. Pneumonia Patient Outcomes Research Team (PORT) Investigators, Med Care, vol.33, pp.56-66, 1995. ,
A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study, Stat Med, vol.26, pp.734-753, 2007. ,
The use of propensity scores in pharmacoepidemiologic research, Pharmacoepidemiol Drug Saf, vol.9, pp.1099-1557, 2000. ,
Adjuvant extension of chemotherapy after neoadjuvant therapy may not improve outcome in early-stage breast cancer, Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol, vol.35, pp.798-804, 2009. ,
, Abstract S1-07: A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04) | Cancer Research, 2019.
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer, JAMA, vol.295, pp.1658-1667, 2006. ,
Clinical Value of Capecitabine-Based Combination Adjuvant Chemotherapy in Early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials, Oncol Res, vol.25, pp.1567-1578, 2017. ,
422 Final Safety Data From a Randomised Phase III Trial (CIBOMA/2004-01_GEICAM/2003-11) Assessing Adjuvant Capecitabine Maintenance Therapy After Standard Chemotherapy for Triple-negative Early Breast Cancer. a Study From Coalicion Iberoamericana De Investigacion En Oncologia Mamaria (CIBOMA) and Grupo Español De Investigacion En Cancer De Mama (GEICAM), Eur J Cancer, vol.48, pp.169-170, 2012. ,
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer, N Engl J Med, vol.380, pp.617-628, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02464524
, Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer-Full Text View-Clinical-Trials.gov, p.15, 2019.